ORTHOReBIRTH
- Company typePrivate
- Founded2011
- HeadquartersYokohama, Japan
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
ORTHOReBIRTH firmographics
Firmographics- Name
- ORTHOReBIRTH
- Legal name
- ORTHOREBIRTH Co., Ltd.
- Website
- https://orthorebirth.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
ORTHOReBIRTH industry classification
Industry- Product category
- Orthopedic Medical Devices - Bone Void Fillers
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industries
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
Keywords
Where ORTHOReBIRTH is headquartered
LocationHeadquarters
- HQ city
- Yokohama
- HQ country
- Japan
- HQ region
- Asia
Offices3 records
Markets served
ORTHOReBIRTH business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- ReBOSSIS Synthetic Bone Products: Sale of cotton-like synthetic bone void fillers (ReBOSSIS series) to healthcare providers through distribution partners across multiple markets including Japan, USA, Taiwan, India, Middle East, and Europe.
- Stem Cell Extraction Culture Sheet: Sale of research-grade cell culture substrates to universities, research institutions, and companies involved in regenerative medicine.
Go-to-market motion1 record
Distribution channels12 records
Marketing channels5 records
ORTHOReBIRTH product offering
Product offeringCore offering
ORTHOREBIRTH designs, manufactures, and distributes bioabsorbable cotton-like synthetic bone void fillers (the ReBOSSIS family) composed primarily of β-TCP and PLGA, used as scaffolds for bone regeneration across orthopedic, spine, neurosurgery, oral/maxillofacial, and plastic surgery applications. The company also sells a Stem Cell Extraction Culture Sheet for Research, a bioabsorbable microfiber scaffold developed with the University of the Ryukyus that accelerates cell proliferation for regenerative-medicine research. Distribution is handled through exclusive clinical-specialty and regional channel partners across Japan, USA, Taiwan, India, South Korea, the Middle East, and Europe, with manufacturing outsourced to Kaigen Pharma (Otaru) and Nissha.
Product overview
ORTHOREBIRTH is a medical device company specializing in microfiber manufacturing technology for regenerative medicine. The core product portfolio consists of the ReBOSSIS cotton-like synthetic bone filler series (absorbable bone void fillers made from β-TCP and bioabsorbable polymers) and the Stem Cell Extraction Culture Sheet for Research. The ReBOSSIS family includes multiple regional variants: ReBOSSIS-J and ReBOSSIS-JS for orthopedic surgery in Japan (distributed by Nakashima Healthforce and Stryker Japan respectively), and the ReBOSSIS-M series (MS, MT, MK, MC) for maxillofacial, plastic surgery, and neurosurgery distributed by Shofu Biofix, Teijin Medical Technologies, Kyocera, and MC Medical respectively. In international markets, the same technology is sold as BioCera Fibers (U.S., via Kyocera Medical Technologies) and CBF (Japan, via Stryker). The company is also developing a bone regeneration product combining cotton-like synthetic bone with tBMP-2 protein, and an antibacterial version of the cotton-shaped artificial bone.
Differentiator
Problem solved
Functional benefit
Brands
- ReBOSSIS: Cotton-like synthetic bone void filler composed of β-TCP and bioabsorbable polymers. Available in multiple variants for orthopedic, maxillofacial, plastic, and neurosurgery applications.
- BioCera Fibers
- FlexFIBER
- CBF (Cotton Bone Filler)
- ReBOSSIS-M Series
- Stem Cell Extraction Culture Sheet for Research
Products and services
- ReBOSSIS (Cotton-Like Synthetic Bone) Absorbable synthetic bone filler characterized by cotton-like shape and softness, composed primarily of β-TCP (beta-tricalcium phosphate) and PLGA. Used as a scaffold for bone regeneration in orthopedic, spine, neurosurgery, oral/maxillofacial, and plastic surgery. Marketed in USA and Taiwan as ReBOSSIS.
- ReBOSSIS-JS Japan-market orthopedic cotton-like synthetic bone product distributed by Stryker Japan K.K. under PMDA approval number 30300BZX00095A05.
- ReBOSSIS-MS Japan maxillofacial and plastic surgery cotton-like synthetic bone product distributed by Shofu Biofix Inc. (ReBOSSIS-MS); PMDA approval number 30300BZX0095A02.
- ReBOSSIS-MT (ReBOSORB) Japan maxillofacial and plastic surgery cotton-like synthetic bone product distributed by Teijin Medical Technologies Co., Ltd.; PMDA approval number 30300BZX0095A03.
- ReBOSSIS-MK (ReBOSSIS MAXILLOFACIAL) Japan maxillofacial and plastic surgery cotton-like synthetic bone product distributed by Kyocera Corporation; PMDA approval number 30300BZX0095A01.
- ReBOSSIS-MC (ReBOSSIS-CMF) Japan cotton-like synthetic bone product for neurosurgery, maxillofacial, and plastic surgery distributed by MC Medical, Inc. (ReBOSSIS-CMF); PMDA approval number 30300BZX0095A04.
- CBF (Cotton Bone Filler) Brand name used by Stryker Japan K.K. for the cotton-like synthetic bone in the Japanese market for orthopedic applications; sales began July 2025.
- FlexFIBER Brand name used by ATEC Japan Co., Ltd. for ORTHOREBIRTH's cotton-like synthetic bone; sales began February 2026.
- BioCera Fibers / Zenbone (U.S. market variants of ReBOSSIS) U.S. market brand names for ORTHOREBIRTH's cotton-like synthetic bone, marketed by Kyocera Medical Technologies, Inc. since Spring 2024 (BioCera Fibers and BioCera Fibers QDS); Zenbone is an alternate U.S. product name (voluntary recall issued in 2025).
- Stem Cell Extraction Culture Sheet for Research Bioabsorbable microfiber scaffold for stem cell extraction and culture. Accelerates cell proliferation when used as a cell culture substrate; high bio-absorbability allows cultured cell sheets to be implanted along with the scaffold. Sold to universities, research institutions, and regenerative-medicine companies.
Quantifiable outcome
- Products used successfully across multiple clinical fields including orthopedic surgery, oral and maxillofacial surgery, plastic surgery, and neurosurgery
Companies that use ORTHOReBIRTH
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles2 records
ORTHOReBIRTH technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
ORTHOReBIRTH partnerships and signals
Strategic signalPartnerships
22 partnerships are on record, tiered core and minor.
- Lunatus Marketing & Consulting FZCOcoreAgency Agreement for distribution of cotton-like synthetic bone in Middle Eastern countries including UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq. Founded in 2003, Lunatus is based in Dubai, UAE, with investment from Marubeni Corporation since 2022.
- ATEC Japan Co., Ltd.coreDistribution agreement for cotton-like synthetic bone. ATEC Japan began sales of FlexFIBER in February 2026. ATEC Japan is the Japanese subsidiary of ATEC Spine, Inc., a US-based medical device manufacturer.
- Medyssey Co., Ltd.coreSales agreement granting exclusive distribution rights for new bone regeneration product combining ORTHOREBIRTH's cotton-like synthetic bone with tBMP-2. Clinical trials ongoing in USA with Japan trials planned. Medyssey is a South Korean medical device manufacturer specializing in orthopedic and neurosurgical products.
- Stryker Japan K.K.coreManufacturing and sales agreement for cotton-like synthetic bone product. Stryker Japan markets the product under the name CBF (Cotton Bone Filler), with sales for orthopedic applications starting July 2025. Stryker Japan is the Japanese subsidiary of Stryker Corporation, a global leader in medical technology.
- Nissha Co., Ltd.coreContract manufacturing partner for cotton-shaped artificial bone. Nissha began manufacturing in June 2025 with first shipment to the US market. Nissha is a global enterprise operating in industrial materials, devices, and medical technology.
- MC MEDICAL, INC.coreDistribution of ReBOSSIS-MC for neurosurgery, maxillofacial, and plastic surgery in Japan. MC Medical is headquartered in Tokyo.
- KYOCERA CorporationcoreDistribution and sales of ReBOSSIS-MK in the field of maxillofacial and plastic surgery in Japan since November 2022. Kyocera provides medical products such as artificial joints and dental implants.
- TEIJIN MEDICAL TECHNOLOGIES Co., Ltd.coreDistribution and sales of ReBOSSIS-MT in the field of maxillofacial and plastic surgery in Japan since November 2022. Company develops medical devices using bio-degradable and resorbable bone-jointing materials.
- SHOFU BIOFIX INC.coreDistribution and sales of ReBOSSIS-MS in the field of maxillofacial and plastic surgery in Japan since November 2022. SHOFU develops, manufactures, and sells dental materials and equipment.
- NAKASHIMA HEALTHFORCE CO., LTD.coreDistribution and sales of ReBOSSIS-J in the territory of Japan since February 2022. Company develops, manufactures, and sells medical devices such as osteosynthesis materials and spinal fixation devices.
- Kyoto Prefectural University of MedicinecoreJoint research on treatment of osteoporotic vertebral body fractures using ReBOSSIS-J impregnated with PRP (platelet rich plasma). Research conducted by Department of Orthopaedic Surgery, Graduate School of Medicine.
- Gene Techno SciencecoreJoint development agreement for remedy for palatognathous disease combining dental pulp stem cells (owned by Gene Techno Science) with cotton-like bioabsorbable artificial bone (owned by ORTHOREBIRTH). Clinical tests planned.
- KYOCERA Medical Technologies, Inc.coreBusiness alliance agreement for exclusive sales of ReBOSSIS and ReBOSSIS QDS (now BioCera Fibers) across the US market since Fall 2019.
- Dexerials CorporationcoreCapital and business alliance for joint development of more efficient cell culture substrates. Combining ORTHOREBIRTH's fiber scaffolding technology with Dexerials' specialized film development technology.
- University of the RyukyuscoreJoint research on regenerative medicine using adipose-derived stem cells. Development of Stem Cell Extraction and Culture Sheet for Research, commercialized since December 2018. Research aims include treatment of large bone defects, breast reconstruction, and organ regeneration.
- Theradaptive, Inc.coreJoint development with Theradaptive Inc. for practicalizing BMP (Bone Morphogenetic Protein) formulation. Fusing Theradaptive's special protein technology with ORTHOREBIRTH's cotton-shaped bone void fillers to create innovative composite materials for bone regeneration. Theradaptive was established by MIT researchers in 2014.
- CBC Co., Ltd.coreExclusive distribution agreement for ReBOSSIS in Europe. Sales to begin after CE Marking approval. CBC is a trading company operating in multiple fields including chemical resins, electronic materials, medical products, and health-promoting foods.
- Harvester Trading Co., Ltd.minorSales partnership for ReBOSSIS in Taiwan.
- Kaigen Pharma Co., Ltd.coreManufacturing outsourcing partner for ReBOSSIS. All ReBOSSIS products are produced at Kaigen Pharma's factory in Otaru, Hokkaido, under strict production and quality control before shipping to USA, Japan, and Taiwan markets.
- Meiji UniversitycoreJoint development of antibacterial cottony-type synthetic bone-void-filling materials. Meiji University (Dr. Mamoru Aizawa) conducting in-vitro evaluation combining silver with ReBOSSIS and β-TCP for antibacterial properties.
- Keio UniversitycoreJoint development of antibacterial cottony-type synthetic bone-void-filling materials. Keio University (Dr. Mamoru Matsumoto and Dr. Takashi Ishii) conducting in-vivo evaluation using rabbits.
- Nagoya Institute of TechnologycoreDr. Toshihiro Kasuga at Nagoya Institute of Technology is the originator of ReBOSSIS technology. Ongoing collaboration for developing higher-quality synthetic bone materials, new scaffolding materials based on microfiber technology, and antibacterial cotton-like materials.
Scale indicators5 records
Recent moves9 records
Expansion highlights6 records
ORTHOReBIRTH competitors and assessment
Company assessmentBroad incumbents
- Stryker: Stryker is ORTHOREBIRTH's channel partner for the Japanese orthopedic market (CBF brand under Stryker Japan) and also develops and markets its own bone graft substitutes and regenerative biologics, making it both a partner and a direct competitor in bone void fillers.
- Medtronic: Medtronic is one of the largest spine and neurosurgery medical device incumbents and sells bone graft substitutes (including INFUSE rhBMP-2 and MASTERGRAFT) directly to the same orthopedic and spine surgeon customers ORTHOREBIRTH targets.
- DePuy Synthes (Johnson & Johnson MedTech): DePuy Synthes sells chronOS, HEALOS, and other bone void fillers across orthopedics, spine, and CMF, and competes against ORTHOREBIRTH's ReBOSSIS in trauma, spine, and maxillofacial surgery with deeper hospital contracts and a global sales force.
- Baxter International: Baxter markets Actifuse bone graft substitutes and regenerative biologics through its surgical solutions business, competing head-to-head with ORTHOREBIRTH in the orthopedic bone void filler category while offering a broader medtech portfolio.
Emerging players
- Cerapedics: Cerapedics develops peptide-enhanced bone graft substitutes (i-FACTOR) for spine and orthopedic applications, making it a comparable emerging specialist focused on biologics-driven bone regeneration similar to ORTHOREBIRTH's BMP-2 combination product program.
Direct peers
- MTF Biologics: MTF Biologics is the largest tissue bank in the U.S. and supplies allograft bone grafts and demineralized bone matrices used as alternatives to ORTHOREBIRTH's synthetic bone void fillers in orthopedic, spine, and reconstructive surgery.
- Bioventus: Bioventus is a focused orthobiologics company selling bone graft substitutes (e.g., OSTEOAMP, Signafuse), addressing the same orthopedic and spine surgeon call points as ORTHOREBIRTH with a similar mid-sized specialist footprint.
- Integra LifeSciences: Integra LifeSciences sells a broad portfolio of bone graft substitutes and regenerative technologies (e.g., Integra OMNIGRAFT, DynaGraft, Accell) across orthopedic, spine, craniomaxillofacial, and neurosurgery indications — directly comparable to ORTHOREBIRTH's cotton-like synthetic bone filler across the same surgical specialties and surgeon call points.
- Geistlich Pharma: Geistlich's Bio-Oss and Bio-Gide lines are the leading bone graft and collagen products in the global dental/oral and maxillofacial surgery market, directly comparable to ORTHOREBIRTH's ReBOSSIS-M series for oral/maxillofacial and plastic surgery applications.
Others
- Theradaptive: Theradaptive is ORTHOREBIRTH's explicit co-development partner (since Oct 2018) for combining its engineered protein technology with ORTHOREBIRTH's cotton-shaped bone void fillers; it is an adjacent enabling technology partner in the BMP-2 bone regeneration product pipeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ORTHOReBIRTH social profiles
Digital presenceORTHOReBIRTH compliance and trust
Trust signalCompliance2 records
ORTHOReBIRTH financial estimates
Financial estimateRevenue estimate
Valuation estimate
ORTHOReBIRTH leadership team
Management profileNumber of profiles
Profiles9 records
ORTHOReBIRTH funding detail
Funding detailFunding overview
Funding rounds6 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ORTHOReBIRTH M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ORTHOReBIRTH
What does ORTHOReBIRTH do?
ORTHOREBIRTH designs, manufactures, and distributes bioabsorbable cotton-like synthetic bone void fillers (the ReBOSSIS family) composed primarily of β-TCP and PLGA, used as scaffolds for bone regeneration across orthopedic, spine, neurosurgery, oral/maxillofacial, and plastic surgery applications. The company also sells a Stem Cell Extraction Culture Sheet for Research, a bioabsorbable microfiber scaffold developed with the University of the Ryukyus that accelerates cell proliferation for regenerative-medicine research. Distribution is handled through exclusive clinical-specialty and regional channel partners across Japan, USA, Taiwan, India, South Korea, the Middle East, and Europe, with manufacturing outsourced to Kaigen Pharma (Otaru) and Nissha.
Is ORTHOReBIRTH a public or private company?
ORTHOReBIRTH is a private company. It is classified as venture growth investor backed and is currently operating.
When was ORTHOReBIRTH founded?
ORTHOReBIRTH was founded in 2011. It employs 11 to 50 people.
Where is ORTHOReBIRTH based?
ORTHOReBIRTH is headquartered in Yokohama, Japan, in the Asia region.
How does ORTHOReBIRTH make money?
Two revenue lines are on record. ReBOSSIS Synthetic Bone Products are the primary driver. The others are stem Cell Extraction Culture Sheet.
Who are ORTHOReBIRTH's main competitors?
Broad incumbents on record are Stryker, Medtronic, DePuy Synthes (Johnson & Johnson MedTech) and Baxter International. Cerapedics is listed as an emerging player. Direct peers are MTF Biologics, Bioventus, Integra LifeSciences and Geistlich Pharma. Theradaptive is listed as an others.
Does ORTHOReBIRTH have an API?
No public API is recorded for ORTHOReBIRTH.
What industry is ORTHOReBIRTH in?
ORTHOReBIRTH's product category is Orthopedic Medical Devices - Bone Void Fillers. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.